Erschienen in:
Diabetes, Obesity and Metabolism (2024)
Sprache:
Englisch
DOI:
10.1111/dom.15566
ISSN:
1462-8902;
1463-1326
Entstehung:
Anmerkungen:
Beschreibung:
<jats:title>Abstract</jats:title><jats:sec><jats:title>Aims</jats:title><jats:p>To describe the overall fat distribution patterns independent of body mass index (BMI) in participants with type 2 diabetes (T2D) in the SURPASS‐3 MRI substudy by comparison with sex‐ and BMI‐matched virtual control groups (VCGs) derived from the UK Biobank imaging study at baseline and Week 52.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>For each study participant at baseline and Week 52 (<jats:italic>N</jats:italic> = 296), a VCG of ≥150 participants with the same sex and similar BMI was identified from the UK Biobank imaging study (<jats:italic>N</jats:italic> = 40 172). Average visceral adipose tissue (VAT), abdominal subcutaneous adipose tissue (aSAT) and liver fat (LF) levels and the observed standard deviations (SDs; standardized normal <jats:italic>z</jats:italic>‐scores: <jats:italic>z</jats:italic>‐VAT, <jats:italic>z</jats:italic>‐aSAT and <jats:italic>z</jats:italic>‐LF) were calculated based on the matched VCGs. Differences in <jats:italic>z</jats:italic>‐scores between baseline and Week 52 were calculated to describe potential shifts in fat distribution pattern independent of weight change.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Baseline fat distribution patterns were similar across pooled tirzepatide (5, 10 and 15 mg) and insulin degludec (IDeg) arms. Compared with matched VCGs, SURPASS‐3 participants had higher baseline VAT (mean [SD] <jats:italic>z</jats:italic>‐VAT +0.42 [1.23]; <jats:italic>p</jats:italic> < 0.001) and LF (<jats:italic>z</jats:italic>‐LF +1.24 [0.92]; <jats:italic>p</jats:italic> < 0.001) but similar aSAT (<jats:italic>z</jats:italic>‐aSAT −0.13 [1.11]; <jats:italic>p</jats:italic> = 0.083). Tirzepatide‐treated participants had significant decreases in <jats:italic>z</jats:italic>‐VAT (−0.18 [0.58]; <jats:italic>p</jats:italic> < 0.001) and <jats:italic>z</jats:italic>‐LF (−0.54 [0.84]; <jats:italic>p</jats:italic> < 0.001) but increased <jats:italic>z</jats:italic>‐aSAT (+0.11 [0.50]; <jats:italic>p</jats:italic> = 0.012). Participants treated with IDeg had a significant change in <jats:italic>z</jats:italic>‐LF only (−0.46 [0.90]; <jats:italic>p</jats:italic> = 0.001), while no significant changes were observed for <jats:italic>z</jats:italic>‐VAT (+0.13 [0.52]; <jats:italic>p</jats:italic> = 0.096) and <jats:italic>z</jats:italic>‐aSAT (+0.09 [0.61]; <jats:italic>p</jats:italic> = 0.303).</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>In this exploratory analysis, treatment with tirzepatide in people with T2D resulted in a significant reduction of <jats:italic>z</jats:italic>‐VAT and <jats:italic>z</jats:italic>‐LF, while <jats:italic>z</jats:italic>‐aSAT was increased from an initially negative value, suggesting a possible treatment‐related shift towards a more balanced fat distribution pattern with prominent VAT and LF loss.</jats:p></jats:sec>